These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30120393)

  • 1. Evaluation of LL-37 antimicrobial peptide derivatives alone and in combination with vancomycin against S. aureus.
    Shurko JF; Galega RS; Li C; Lee GC
    J Antibiot (Tokyo); 2018 Nov; 71(11):971-974. PubMed ID: 30120393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased resistance to cationic antimicrobial peptide LL-37 in methicillin-resistant strains of Staphylococcus aureus.
    Ouhara K; Komatsuzawa H; Kawai T; Nishi H; Fujiwara T; Fujiue Y; Kuwabara M; Sayama K; Hashimoto K; Sugai M
    J Antimicrob Chemother; 2008 Jun; 61(6):1266-9. PubMed ID: 18367458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human antimicrobial peptide, LL-37, induces non-inheritable reduced susceptibility to vancomycin in Staphylococcus aureus.
    Friberg C; Haaber JK; Vestergaard M; Fait A; Perrot V; Levin BR; Ingmer H
    Sci Rep; 2020 Aug; 10(1):13121. PubMed ID: 32753585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic microbicidal effect of cationic antimicrobial peptides and teicoplanin against planktonic and biofilm-encased Staphylococcus aureus.
    Koppen BC; Mulder PPG; de Boer L; Riool M; Drijfhout JW; Zaat SAJ
    Int J Antimicrob Agents; 2019 Feb; 53(2):143-151. PubMed ID: 30315918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible Staphylococcus aureus causing bacteremia by human cathelicidin LL-37.
    Le J; Dam Q; Schweizer M; Thienphrapa W; Nizet V; Sakoulas G
    Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1441-7. PubMed ID: 27234592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
    Fritsche TR; Rhomberg PR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ZnO nanoparticles on methicillin, vancomycin, linezolid resistance and biofilm formation in Staphylococcus aureus isolates.
    Abdelraheem WM; Khairy RMM; Zaki AI; Zaki SH
    Ann Clin Microbiol Antimicrob; 2021 Aug; 20(1):54. PubMed ID: 34419054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial Properties and Efficacy of LL-37 Fragment GF-17D3 and Scolopendin A2 Peptides Against Resistant Clinical Strains of Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii In Vitro and In Vivo Model Studies.
    Farzi N; Oloomi M; Bahramali G; Siadat SD; Bouzari S
    Probiotics Antimicrob Proteins; 2024 Jun; 16(3):796-814. PubMed ID: 37148452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of tick antimicrobial peptide from Ixodes persulcatus (persulcatusin) against cell membranes of drug-resistant Staphylococcus aureus.
    Miyoshi N; Isogai E; Hiramatsu K; Sasaki T
    J Antibiot (Tokyo); 2017 Feb; 70(2):142-146. PubMed ID: 27531221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Small-Molecule Inhibitor of
    Huang Y; Alumasa JN; Callaghan LT; Baugh RS; Rae CD; Keiler KC; McGillivray SM
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30917982
    [No Abstract]   [Full Text] [Related]  

  • 12. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Dilworth TJ; Leonard SN; Vilay AM; Mercier RC
    Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus.
    Dean SN; Bishop BM; van Hoek ML
    BMC Microbiol; 2011 May; 11():114. PubMed ID: 21605457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant staphylococci.
    Mohammad H; Mayhoub AS; Cushman M; Seleem MN
    J Antibiot (Tokyo); 2015 Apr; 68(4):259-66. PubMed ID: 25315757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRSA--the tip of the iceberg.
    Appelbaum PC
    Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():3-10. PubMed ID: 16524422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cationic antimicrobial peptides: alternatives and/or adjuvants to antibiotics active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa.
    Geitani R; Ayoub Moubareck C; Touqui L; Karam Sarkis D
    BMC Microbiol; 2019 Mar; 19(1):54. PubMed ID: 30849936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of antimicrobial peptide LL-37 for treatment of Staphylococcus aureus biofilm on titanium plate.
    Wei J; Cao X; Qian J; Liu Z; Wang X; Su Q; Wang Y; Xie R; Li X
    Medicine (Baltimore); 2021 Nov; 100(44):e27426. PubMed ID: 34871207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.
    Hiramatsu K; Aritaka N; Hanaki H; Kawasaki S; Hosoda Y; Hori S; Fukuchi Y; Kobayashi I
    Lancet; 1997 Dec; 350(9092):1670-3. PubMed ID: 9400512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus.
    Singh NB; Yim J; Jahanbakhsh S; Sakoulas G; Rybak MJ
    Diagn Microbiol Infect Dis; 2018 Aug; 91(4):363-370. PubMed ID: 29807674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
    Saravolatz L; Pawlak J; Johnson L
    Antimicrob Agents Chemother; 2010 Jul; 54(7):3027-30. PubMed ID: 20404122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.